|
|
Expected minimum level |
|
Surveillance |
| 1 |
Cases with "unknown" hospitalization |
<= 5% |
| 2 |
Hospitalized cases with "unknown" outcome |
<= 1% |
| 3 |
Completion of information on age |
>= 95% |
| 4 |
Completion of information on sex |
>= 95% |
| 5 |
Completion of information on race |
|
|
5a. Campylobacter |
>=75% |
|
5b. Cryptosporidium |
>=85% |
|
5c. Cyclospora |
>=85% |
|
5d. Listeria |
>= 90% |
|
5e. Salmonella |
>= 85% |
|
5f. Shigella |
>=85% |
|
5g. STEC |
>= 90% |
|
5h. Vibrio |
>= 90% |
|
5i. Yersinia |
>=80% |
| 6 |
Completion of information on ethnicity |
|
|
6a. Campylobacter |
>=75% |
|
6b. Cryptosporidium |
>=85% |
|
6c. Cyclospora |
>=85% |
|
6d. Listeria |
>=90% |
|
6e. Salmonella |
>=85% |
|
6f. Shigella |
>=85% |
|
6g. STEC |
>=90% |
|
6h. Vibrio |
>=90% |
|
6i. Yersinia |
>=80% |
| 7 |
Completion of information on international travel |
|
|
7a. Campylobacter |
>=65% |
|
7b. Cryptosporidium |
>=75% |
|
7c. Cyclospora |
>=75% |
|
7d. Listeria |
>=90% |
|
7e. Salmonella |
>= 90% |
|
7f. Shigella |
>=75% |
|
7g. STEC |
>=90% |
|
7h. Vibrio |
>=90% |
|
7i. Yersinia |
>=75% |
| 8 |
Completion of outbreak supplemental forms |
>=75% |
| 9 |
Outbreak-associated cases with NORS number (all pathogens) |
100% |
| 10 |
Outbreak type reported for outbreak associated cases (all pathogens) |
98% |
| 11 |
Median # of days from culture collection to data entry |
<= 10 days |
| 12 |
Median number of days from diagnosis of HUS case to data entry |
<=60 days |
| 13 |
HUS cases with information on diarrheal status |
100% |
| 14 |
Completion of HDD review within two years of case onset |
100% |
| 15 |
Completion of BioID for all cases of STEC infection |
100% |
| 16 |
Completion of BioID for all cases of Campylobacter infection |
100% |
| 17 |
Completion of symptom*information for culture-confirmed cases of Campylobacter infection |
50% |
| 18 |
Completion of symptom* information for culture-independent cases of Campylobacter infection |
50% |
| 19 |
Submission of national case report forms |
|
|
19a. Cholera and Other Vibrio Illness |
100% |
|
19b. Salmonella Typhi and Salmonella Paratyphi |
100% |
|
19c. Listeria |
100% |
|
Laboratory Information |
| 20 |
Isolates from clinical labs received at state public health labs (based on presence of state laboratory ID number) |
|
|
20a. Salmonella |
>= 85% |
|
20. E. coli O157 |
>= 95% |
|
20c. Listeria monocytogenes |
>= 95% |
|
20d. Vibrio |
>= 90% |
| 21 |
Isolates with serotype/species in FoodNet active surveillance |
|
|
21a. Campylobacter |
>=50% |
|
21b. Salmonella |
>= 95% |
|
21b. Shigella |
>= 95% |
|
21c. Vibrio |
>= 95% |
|
21d. Yersinia |
>= 95% |
| 22 |
NARMS isolates received at CDC (NARMS received/Total FoodNet sent to SPHL) |
|
|
22a. Non-typhoidal Salmonella (every 20th) |
5% |
|
22b. E. coli O157 (every 20th) |
5% |
|
22c. Shigella (every 20th) |
5% |
|
22d. Salmonella Typhi (all) |
100% |
|
22e. Vibrio (all) |
100% |
|
22f. Campylobacter |
Varies by state |
| 23 |
Pulsenet patterns submitted to CDC |
|
|
23a. E.coli O157:H7 |
100% |
|
23b. Salmonella Typhi |
100% |
|
23c. Listeria monocytogenes |
100% |
|
Case-Control, Cohort, and Other Studies |
| 24 |
Percent of “eligible” (not excluded per study protocol) cases enrolled |
> 50% of eligible** |
|
Leadership |
| 25 |
Site participation in steering committee calls |
100% |
| 26 |
Site principal investigator attendance at Vision Meeting |
100% |
| 27 |
Site principal investigator attendance at annual principal investigator meeting(s) |
100% |
| 28 |
Site coordinator attendance at annual coordinator meeting(s) |
100% |
| *diarrhea, bloody diarrhea, and fever; greatest effort should be placed on obtaining this information on cases for which isolates are submitted to NARMS |
| **assessed for each study |
|
|